ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0753

Treatment and Evolution in 134 Patients with Aortitis and Periaortitis. Experience of a Single Referral Centre

Carmen Secada Gómez1, Javier Loricera2, Adrián Martín-Gutiérrez3, Fernando Lopez-Gutierrez4, Santos Castañeda5 and Ricardo Blanco-Alonso6, 1Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 2Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 3Hospital Universitario Marques de Valdecilla, IDIVAL, Renedo de Piélagos, Cantabria, Spain, 4Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Cantabria, Spain, 5Hospital Universitario de la Princesa, Madrid, Spain, 6Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain

Meeting: ACR Convergence 2024

Keywords: corticosteroids, giant cell arteritis, IgG4 Related Disease, Takayasu.s arteritis, Vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: Vasculitis – Non-ANCA-Associated & Related Disorders Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Aortitis and periaortitis include a heterogeneous group of entities that may be idiopathic or secondary to infectious and non-infectious processes. Therefore, treatment will differ considerably depending on the underlying cause.  Our aim was to assess therapy and the response in a wide series of patients with aortitis or periaortitis from a single university center.

Methods: Observational study of patients with aortitis or periaortitis from a referral center in Spain. Outcomes were: clinical remission (absence of clinical symptoms), complete remission (absence of clinical symptoms and analytical normalization), and absence of systemic inflammation (complete remission and imaging remission) . Safety was also evaluated.

Results: We included 134 patients (87 female/47 male) (mean age: 55.1±9.1 years) with aortitis (n=132) or periaortitis (n=2) related to different diseases. They were treated with glucocorticosteroids (n=127; 94.8%), immunosuppressive synthetic drugs (68; 50.7%), biologic therapy (n= 48; 35.8%), antibiotics (n=3; 1.5%) and surgery (n=6; 4,5%) (Table 1). Adverse effects registered were: abdominal pain (n=6, 4.5%), vomit (n=3, 2.2%), anxiety (n=3, 2.2%), diarrhoea (n=2 , 1.5%) , tremor (n=1, 0.7%), increase appetite (n=1, 0.7%) , pyrosis (n=1, 0.7%), asthenia (n=1, 0.7%) and dyspnoea (n=1, 0.7%) . After a follow-up of 39.2±26.7 months, 19 patients (14.2%) experimented clinical remission, 64 (47.8%) complete remission and 16 (11.9%) absence of systemic inflammation (Figure 1). At the diagnosis, 18F-FDG PET/CT scan was positive in all patients, during the follow up 18F-FDG PET/CT scan was performed in 87 patients (65%) . The mean time between baseline and follow up 18F-FDG PET/CT scans was 18.1±15.1 months, observing the following changes in 18F-FDG uptake: absent (n= 20, 23%), decrease (n=32, 36.8%), similar uptake (n= 22, 25.3%) and increase (n= 13 , 14.9%) (Figure 2).

Conclusion: Aortitis and periaortitis are entities that require an early treatment. Corticosteroids are the first line of treatment in patients with non-infectious aortitis or periaortitis.  18F-FDG PET/CT scan is a useful imaging technique to evaluate the activity and response to different treatments.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: C. Secada Gómez: None; J. Loricera: AstraZeneca, 2, 6, Celgene, 2, 6, Eli Lilly, 5, Janssen, 5, Merck/MSD, 2, 5, 6, Novartis, 12, Formation/Congress attendance, Pfizer, 5, Roche, 2, 5, 6, UCB, 2, 5, 6; A. Martín-Gutiérrez: None; F. Lopez-Gutierrez: AstraZeneca, 12, Formation/Congress attendance, 12, Formation/Congress attendance, Novartis, 12, Formation/congress attendance; S. Castañeda: Bristol-Myers Squibb(BMS), 2, 6, Eli Lilly, 2, 6, Merck/MSD, 2, 5, 6, Pfizer, 5, Roche, 2, 6, UCB, 2, 5; R. Blanco-Alonso: AbbVie, 2, 5, 6, Bristol-Myers Squibb, 2, 6, Galapagos, 6, Janssen, 2, 6, Lilly, 2, 6, MSD, 2, 5, 6, Pfizer, 2, 6, Roche, 2, 5, 6.

To cite this abstract in AMA style:

Secada Gómez C, Loricera J, Martín-Gutiérrez A, Lopez-Gutierrez F, Castañeda S, Blanco-Alonso R. Treatment and Evolution in 134 Patients with Aortitis and Periaortitis. Experience of a Single Referral Centre [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/treatment-and-evolution-in-134-patients-with-aortitis-and-periaortitis-experience-of-a-single-referral-centre/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/treatment-and-evolution-in-134-patients-with-aortitis-and-periaortitis-experience-of-a-single-referral-centre/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology